Associated Papers
KRAS or BRAF mutations cause hepatic vascular cavernomas treatable with MAP2K-MAPK1 inhibition.
Janardhan HP et al.
The Journal of Experimental Medicine, 2020
A subset of lung adenocarcinomas and atypical adenomatous hyperplasia-associated foci are genotypically related: an EGFR, HER2, and K-ras mutational analysis.
Sartori G et al.
American Journal of Clinical Pathology, 2008
Select a paper to view details